National Safety Council report shows progress in safety cultures, gaps in risk reduction and innovationWASHINGTON, Dec. 15, ...

A worker at a special court that helps Auckland's homeless who have committed low-level crimes turn their lives around, says ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Each dose of our kennel cough vaccine comprises a vial of lyophilisate, which is reconstituted with a solvent to produce 0.4mls of liquid, containing millions of live Bordetella bronchiseptica ...

A tumor-informed ctDNA assay identified MRD in TNBC patients, indicating a 30-fold higher risk of distant recurrence for MRD-positive individuals. The NSABP B-59/GBG 96-GeparDouze trial involved 1550 ...

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

The democratic socialist running in New York's 12th district told Newsweek "you cannot be a tame politician right now." ...

"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

BERLIN — Adding durvalumab (Imfinzi) to the standard perioperative regimen for patients with early adenocarcinoma of the upper gastrointestinal tract improves overall survival, according to findings ...

On September 11, 2025, after MSNBC's view of the shooting of Charlie Kirk, Joe Rogan and Charlie Sheen were shocked. The day before, while giving a lecture at Utah Valley University in Orem, Utah ...

MSD (Merck & Co., Inc.) will vacate its laboratories at the Francis Crick Institute in London by end‑2025 as it winds down discovery research in the UK. The move follows the decision to scrap a ...